Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Exenatide vs Mazdutide: they're closely matched on evidence (6 vs 5/10); they're alternatives for manage weight — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Exenatide and Mazdutide are closely matched across evidence, studies, and safety.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Exenatide and Mazdutide have evidence — compare verdict strength side-by-side.
Prescription-only, clinician-directed. Subcutaneous. Byetta (twice-daily): 5 µg before two main meals, escalated to 10 µg after ~1 month. Bydureon (once-weekly extended-release): 2 mg subcutaneously once weekly. DO NOT self-dose.
any
Once-weekly extended-release injection (Bydureon)
Investigational / China-only dosing: once-weekly subcutaneous injection, dose-escalated over several weeks. Trial maintenance doses studied were 4 mg, 6 mg, and 9 mg once weekly (lower doses used during titration to limit GI effects). There is no FDA-approved regimen.
anytime
Once-weekly subcutaneous injection (investigational; China-approved as Xinermei)
Weeks to months
Months
Years
Especially early / during dose escalation
Months (dose-escalated)
Weeks to months
Weeks to months
Mostly during titration
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL).
N Engl J Med (2017) · Rct · n=14752
Large cardiovascular-outcomes RCT: 14,752 patients with type 2 diabetes (73.1% with prior cardiovascular disease), once-weekly exenatide 2 mg vs placebo added to usual care, median 3.2 years
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes (DURATION-1): a randomised, open-label, non-inferiority study.
Lancet (2008) · Rct · n=295
30-week open-label RCT in 295 patients with type 2 diabetes comparing once-weekly extended-release exenatide 2 mg with 10 µg twice daily
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
Lancet (2013) · Rct · n=911
26-week head-to-head open-label RCT in 911 patients: once-weekly exenatide 2 mg vs once-daily liraglutide 1.8 mg added to oral therapy
Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.
JAMA (2026) · Rct · n=461
60-week phase-3 double-blind placebo-controlled RCT (GLORY-2) in 461 Chinese adults with obesity (BMI >=30), mazdutide 9 mg vs placebo
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.
N Engl J Med (2025) · Rct · n=610
48-week phase-3 double-blind placebo-controlled RCT (GLORY-1) in 610 Chinese adults with overweight/obesity, mazdutide 4 mg or 6 mg vs placebo
Mazdutide versus placebo in Chinese adults with type 2 diabetes.
Nature (2026) · Rct · n=320
Phase-3 RCT in 320 Chinese adults with type 2 diabetes inadequately controlled on diet/exercise, mazdutide 4/6 mg vs placebo for 24 weeks
Both Exenatide and Mazdutide are closely matched — the best choice depends on your specific health goals.
For manage weight, Mazdutide has a higher relevance score (66 vs 46).
No known interactions between Exenatide and Mazdutide have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.